High Hopes, Low Sales: Aduhelm’s Dismal Roll-Out and What’s Next for Anti-Amyloids
Controversial Alzheimer’s drug Aduhelm underwhelmed in early sales. Despite poor performance, some neurologists hope the drug will mean more new Alzheimer’s treatments — and…